Glipizide (Glucotrol) and Black patients
Brand names: Glucotrol
What Glipizide does
Glipizide is a second-generation sulfonylurea that stimulates pancreatic beta cells to release insulin. It lowers blood glucose reliably, has been generic for decades, and costs pennies per pill. It causes hypoglycemia and modest weight gain, and it lacks the cardiovascular or kidney benefit of newer diabetes drug classes.
What the evidence says for Black patients
Sulfonylureas work similarly across racial groups. But the ADOPT trial (Kahn et al., NEJM 2006;355:2427–43, PMID 17145742) showed glyburide (a related sulfonylurea) produced more hypoglycemia and less durable glycemic control than metformin or rosiglitazone over 5 years. Glipizide shares this class limitation.
For Black patients, sulfonylureas have two specific concerns:
- Hypoglycemia risk. Black patients are more likely to work shift jobs, have food insecurity, and have less predictable meal timing — all risk factors for sulfonylurea-induced hypoglycemia. This can masquerade as non-adherence.
- Cost vs. outcome trade-off. Glipizide is inexpensive and widely covered. When a Black patient cannot afford a GLP-1, SGLT2, or even metformin combination, glipizide is better than uncontrolled hyperglycemia — but the goal should be transitioning to a regimen with outcome benefits as soon as coverage allows.
The ADA 2024 Standards of Care position sulfonylureas as second- or third-line therapy, primarily for cost-driven prescribing.
Common alternatives
Metformin (first-line), SGLT2 inhibitors (empagliflozin, dapagliflozin — generic versions now approved), or GLP-1 receptor agonists if cost allows. DPP-4 inhibitors (sitagliptin, linagliptin) are a lower-cost alternative without hypoglycemia risk.
Side effects
- Hypoglycemia — most important risk; can be severe and prolonged
- Weight gain
- Photosensitivity
- Rare hepatic dysfunction
- Cross-reactivity with sulfa allergy is clinically rare but possible
Factors that affect adherence
Take glipizide 30 minutes before breakfast; taking it without eating guarantees hypoglycemia. Patients who fast (Ramadan, labs, religious fasts) should skip the dose. Generic glipizide is on every $4 pharmacy list; cost is not a barrier.
Questions to ask your doctor
Bring this list to your next appointment.
- Can we try metformin plus an SGLT2 instead of a sulfonylurea?
- What do I do if I feel low blood sugar?
- Should I hold this if I'm fasting or skipping meals?
References
- Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy (ADOPT). NEJM. 2006;355:2427–2443. PMID 17145742.
- American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S158–S178.
- U.S. Food and Drug Administration. Glucotrol (glipizide) label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017783s033s035,018991s041s043lbl.pdf
Medical disclaimer
This page is patient education, not prescribing guidance. It summarizes the published evidence about how this medication has been studied in Black patients — it is not a substitute for the judgment of your personal clinician. Never start, stop, or change a prescription based on something you read here. If you have questions about your medication, call your prescriber or pharmacist. For emergencies, call 911.
Read our editorial standards for how we source, review, and update these pages.